Impaired Virologic Response to Highly Active Antiretroviral Therapy Associated With Ongoing Injection Drug Use
- 1 April 2003
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 32 (5) , 522-526
- https://doi.org/10.1097/00126334-200304150-00009
Abstract
Injection drug users who continue to use drugs may not respond to highly active antiretroviral therapy (HAART) as well as other HIV-infected individuals, even after adjusting for a reliable measure of adherence. We therefore compared the virologic response among participants in a population-based HIV/AIDS Drug Treatment Program in British Columbia, Canada, by injection drug use activity. Participants who were HIV infected and naive to antiretroviral therapy and who were prescribed antiretroviral treatment between August 1996 and December 2000 were eligible for this study. They were classified as current, former, or non-injection drug users. The main outcome was having two consecutive HIV-1 RNA levels less than 500 copies/mL. We used logistic regression to adjust for baseline HIV-1 RNA, type of antiretroviral regimen (2 nucleosides + nonnucleoside reverse transcriptase inhibitor versus 2 nucleosides + protease inhibitor), duration of therapy (months), adherence (derived from refill compliance data), and age. A total of 578 participants were first prescribed HAART during the study period. Among them, 78 (13%) were current injection drug users, 96 (17%) were former injection drug users, and 404 (70%) never injected drugs. In the multivariable logistic regression, relative to non-drug users, current injection drug users were significantly less likely to suppress their HIV-1 RNA (adjusted OR [AOR] = 0.30, 95% CI: 0.13–0.67), and former injection drug users were not significantly different from non-drug users (AOR = 0.56, 95% CI: 0.24–1.34). There was a significant interaction between drug use and adherence. In the analyses stratified by drug use, the adherence of former and non-drug users was positively associated with HIV-1 RNA suppression (AOR = 1.33, 95% CI: 1.14–1.55), whereas for current drug users, it was not (AOR = 1.07, 95% CI: 0.87–1.33). Current injection drug users were less likely to achieve HIV-1 RNA suppression compared with non-drug users. Adherence as measured by pharmacy refill compliance was not a reliable measure in this subpopulation.Keywords
This publication has 26 references indexed in Scilit:
- Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV InfectionAnnals of Internal Medicine, 2000
- Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1New England Journal of Medicine, 2000
- A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and SurvivalJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: Adherence, side effects and efficacyJournal of Infection, 1999
- Public Health Implications of Antiretroviral Therapy and HIV Drug ResistanceJAMA, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral TherapyJAMA, 1998
- A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous ExposureNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Effect of antiviral treatment on the shedding of HIV-1 in semenAIDS, 1997